Cargando…
Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylate...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394488/ https://www.ncbi.nlm.nih.gov/pubmed/25764160 http://dx.doi.org/10.3390/ijms16035497 |
_version_ | 1782366295870668800 |
---|---|
author | Michelin, Márcia Antoniazi Montes, Letícia Nomelini, Rosekeila Simões Trovó, Marco Aurélio Murta, Eddie Fernando Candido |
author_facet | Michelin, Márcia Antoniazi Montes, Letícia Nomelini, Rosekeila Simões Trovó, Marco Aurélio Murta, Eddie Fernando Candido |
author_sort | Michelin, Márcia Antoniazi |
collection | PubMed |
description | Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4(+) T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4(+) T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4(+) T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern. |
format | Online Article Text |
id | pubmed-4394488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-43944882015-05-21 Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α Michelin, Márcia Antoniazi Montes, Letícia Nomelini, Rosekeila Simões Trovó, Marco Aurélio Murta, Eddie Fernando Candido Int J Mol Sci Article Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4(+) T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4(+) T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4(+) T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern. MDPI 2015-03-10 /pmc/articles/PMC4394488/ /pubmed/25764160 http://dx.doi.org/10.3390/ijms16035497 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Michelin, Márcia Antoniazi Montes, Letícia Nomelini, Rosekeila Simões Trovó, Marco Aurélio Murta, Eddie Fernando Candido Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title | Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title_full | Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title_fullStr | Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title_full_unstemmed | Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title_short | Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α |
title_sort | helper t lymphocyte response in the peripheral blood of patients with intraepithelial neoplasia submitted to immunotherapy with pegylated interferon-α |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394488/ https://www.ncbi.nlm.nih.gov/pubmed/25764160 http://dx.doi.org/10.3390/ijms16035497 |
work_keys_str_mv | AT michelinmarciaantoniazi helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona AT montesleticia helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona AT nomelinirosekeilasimoes helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona AT trovomarcoaurelio helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona AT murtaeddiefernandocandido helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona |